Clinical guidance on the perioperative use of targeted agents in solid tumor oncology

Asia-Pacific Journal of Clinical Oncology

Volumn 7, Issue 2, 2011, Pages 106-113

  Mellor, James D ^a   Cassumbhoy, Michelle ^a   Jefford, Michael ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

EGFR; Oncology; Perioperative; Surgery; Targeted agent; VEGF; Wound healing

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IMATINIB; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; SORAFENIB; SUNITINIB; VASCULOTROPIN;

ADVANCED CANCER; BLEEDING; BLISTER; BREAST CANCER; COLORECTAL CANCER; DATA ANALYSIS; DRUG HALF LIFE; DRUG SURVEILLANCE PROGRAM; ERYTHEMA; EVIDENCE BASED PRACTICE; GLIOBLASTOMA; HALF LIFE TIME; HEAD AND NECK CANCER; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MEDICAL RECORD; ONCOLOGY; PERIOPERATIVE COMPLICATION; PERIOPERATIVE PERIOD; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN DEFECT; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; SWELLING; WOUND; WOUND DEHISCENCE; WOUND HEALING; WOUND HEALING IMPAIRMENT;

ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PERIOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS;

EID: 79956123084     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2011.01394.x     Document Type: Review

References (36)

1. MIMS Online. Full Product Information for Avastin. Roche Products Pty Ltd; Approved 9 December 2008 (Updated 23 August 2010). Available from Accessed 5 April 2011.
2. Fernando NH, Hurwitz HI. Inhibition of vascular endothelia growth factor in the treatment of colorectal cancer. Semin Oncol 2003; 30 (Suppl 6):39-50.
3. Ellis LM, Curley SA, Grothey A. Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol 2005; 23: 4853-5.
4. Beckwith C, Tyler L (eds). Cancer Chemotherapy Manual 2007. Wolters Kluwer Health University of Utah, Salt Lake City 2007.
5. Scappaticci F, Fehrenbacher T, Cartwright J etal. Lack of effect of bevacizumab on wound healing/bleeding complications when given 28-60days following primary cancer surgery. 2004 ASCO Annual Meeting Proceedings. J Clin Oncol 2004; 22: 14s (Suppl; abstr 3530).
6. Miller K, Wang M, Gralow J etal. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. New Engl J Med 2007; 357: 2666-76.
7. BC Cancer Agency. Cancer Management Guidelines. Management guidelines of bevacizumab related side effects. 2006 (latest revision of text). Available from URL: (accessed 29 March 2011).
8. Berry S, Kretzschmar M, Cunningham D etal. Lack of effect of starting bevacizumab shortly after venous access device implantation on wound healing/bleeding complications: preliminary results from first BEAT. Proceedings. 2006 ASCO Gastrointestinal Cancers Symposium, San Francisco, p. 208 (abstract 245).
9. Van Cutsem E, Rivera F, Berry S etal. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009; 11: 1842-7.
10. Parikh AA, Ellis LM. Targeted therapies and surgical issues in gastrointestinal cancers. Targeted Oncol 2008; 3: 119-25.
11. Spigel D, Hainsworth J, Yardley D etal. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol 2010; 28: 43-8.
12. Sher AF, Chu D, Wu S. Risk of bleeding in cancer patients treated with the angiogenesis inhibitor bevacizumab: a meta-analysis. Proceedings. 2009 ASCO Annual Meeting. J Clin Oncol 2009; 27: 15s (Suppl; abstr 9584).
13. Golshan M, Garber J, Gelman R etal. Does neoadjuvant bevacizumab increase surgical complications in breast surgery? Annals Surg Oncol 2011; 18: 733-7.
14. Friedman HS, Prados MD, Wen PY etal. Bevaczumab alone and in combination with irinotecan in recurrent glioblastoma. Journal Clinical Oncology 2009; 27: 4733-40.
15. MIMS Online. Full Product Information for Sutent. Pfizer Australia Pty Ltd; Approved 14 April 2008 (Updated 12 December 2010). Available from Accessed 5 April 2011.
16. Raut CP, Morgan JA, Quigley MT etal. Postoperative experiences in patients with metastatic GIST are similar in patients while on sunitinib or imatinib (Poster). 14th European Cancer Conference (ECCO) 2007 (Barcelona).
17. Raut CP, Morgan JA, Quigley MT etal. Peri operative sunitinib dosing around extensive resections of imatinib resistant metastatic gastrointestinal stromal tumours. 2007 ASCO Annual Meeting Proceedings. J Clin Oncol 2007; 25 (Suppl. 18S):10044.
18. Thibaoult F, Billemont B, Rixe O. Peri operative use and surgical complications of sunitinib in metastatic renal cell carcinoma. Eur Urol Suppl 2008; 7: 306.
19. Van der Veldt AAM, Meijerink MR, van den Eertwegh AJM etal. Sunitinib for treatment of advanced renal cell cancer: primary tumour response. Clin Cancer Res 2008; 14: 2431-6.
20. Feyerabend S, Schilling D, Wicke C, Stenzl A. Toxic dermatolysis, tissue necrosis and impaired wound healing due to sunitinib treatment leading to foot amputation. Orologia Internationalis 2009; 82: 246-8.
21. Je Y, Schutz FAB, Choueiri TK. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol 2009; 10: 967-74.
22. Desai J, Gurney H, Pavlakis N, McArthur G, Davis ID. Sunitinib malate in the treatment of renal cell carcinoma and gastrointestinal stromal tumor: recommendations for patient management. Asia Pacific J Clin Oncol 2007; 3: 167-76.
23. MIMS Online. Full Product Information for Nexavar. Bayer Schering; Approved 7 August 2009. Available from Accessed 5 April 2011.
24. Cowey CL, Amin C, Pruthi RS etal. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol 2010; 28: 1502-7.
25. Eng FCS, Easson AM, Szentgyorgyi E, Knox JJ. Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinoma. Eur J Surg Oncol 2009; 35: 219-21.
26. MIMS Online. Full Product Information for Erbitux. Merck Serono Australia Pty Ltd; Approved 20 July 2007 (Updated 5 January 2010). Available from Accessed 5 April 2011.
27. th annual ASTRO meeting. Int J Radiat Oncol Biol Physics 2003; 57: 2 Supplement.
28. Forester CG, Cursiefen C, Kruse FE. Persisting corneal erosion under cetuximab (Erbitux) treatment (epidermal growth factor receptor antibody). Cornea 2008; 27: 612-14.
29. Sorensen M, Bernhardtsen Gaziel T, Hasselbalch B, Poulsen H, Lassen U. Severe skin lesions in patients with glioblastoma multiforme treated with a combination of cetuximab, bevacizumab and irinotecan. Proc EJCMO 2010; 2: 73-75.
30. MIMS Online. Full Product Information for Tarceva. Roche Products Pty Ltd; Approved 24 March 2009 (Updated 15 December 2010). Available from Accessed 5 April 2011.
31. Lee SM, Buchler T, Joseph T, Lai C. Bilateral eardrum perforation after long term treatment with erlotinib. J Clin Oncol 2008; 26: 2582-4.
32. MIMS Online. Full Product Information for Iressa. AstraZeneca Pty Ltd; Approved 5 March 2009 (Updated 29 June 2010). Available from Accessed 5 April 2011.
33. Govindan R, Behnken D, Read W, McLeod H. Wound healing is not impaired by the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib. Annals Oncol 2003; 14: 1330-1.
34. MIMS Online. Full Product Information for Vectibix. Amgen Australia Pty Ltd; Approved 7 April 2009 (Updated 22 September 2010). Available from Accessed 5 April 2011.
35. US Prescribing Information for Vectibix. Amgen Inc.; 2006 Available from Accessed 5 April 2011.
36. Keating GM. Panitumumab: a review of its use in metastatic colorectal cancer. Drugs 2010; 70: 1059-78.